Aquestive Therapeutics, Inc. (AQST)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Aquestive Therapeutics, Inc. reported revenue of $44.55M, down 22.6% from the prior year. The company ran a net loss, with a net margin of -188.1%. It held $160.43M in total assets against $194.09M in total liabilities.
Key ratios (FY2025)
-159.5%
Operating margin
-188.1%
Net margin
-22.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.55M | $57.56M | $50.58M | $47.68M | $50.83M | $45.85M | $52.61M | $67.43M | — | — |
| Cost of Revenue | $18.55M | $17.87M | $20.83M | $19.39M | — | $12.96M | $20.36M | — | — | — |
| Operating Income | -$71.05M | -$30.77M | -$15.10M | -$42.07M | -$34.68M | -$42.89M | -$52.67M | -$48.93M | -$113.0K | — |
| Net Income | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -$70.54M | -$55.78M | -$66.25M | -$61.38M | -$8.94M | — |
| EPS (Diluted) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 | $-1.66 | — | — | — | — |
| Total Assets | $160.43M | $101.42M | $57.42M | $57.07M | $61.99M | $62.88M | $78.48M | $86.85M | $43.12M | — |
| Total Liabilities | $194.09M | $161.58M | $163.91M | $175.62M | $144.13M | $111.38M | $84.60M | $76.77M | $69.61M | — |
| Shareholders' Equity | -$33.66M | -$60.16M | -$106.49M | -$118.55M | -$82.13M | -$48.50M | -$6.12M | $10.08M | -$26.50M | -$57.20M |
| Cash & Equivalents | — | — | — | — | — | $31.81M | $49.33M | $60.60M | $17.38M | $9.21M |
| Operating Cash Flow | -$52.43M | -$35.76M | -$6.38M | -$9.82M | -$32.98M | -$45.46M | -$60.21M | -$12.99M | $5.82M | — |
| Capital Expenditures | $562.0K | $159.0K | $995.0K | $1.02M | $913.0K | $517.0K | $663.0K | $1.82M | $2.07M | — |
| Shares Outstanding | 122.04M | 91.41M | 68.53M | 54.83M | 41.23M | 34.57M | 33.56M | 24.96M | — | — |